Introduction
The rat uterus exhibits variations in its prostaglandin (PG) synthesizing capacity during the oestrous cycle (Poyser & Scott, 1980) and during pseudopregnancy (Fenwick, Jones, Naylor, Poyser & Wilson, 1977) . 6-Oxo-PGF-la, reflecting prostacyclin (PGI-2) production, is the major PG formed together with smaller quantities of PGF-2a and PGE-2. During the 4-day oestrous cycle, peak PG production occurs on Day 1 (oestrus), declines on Days 2 and 3, and starts to recover on Day 4. During pseudopregnancy, a similar trend is observed in PGF-2a and PGE-2 production (6-oxo-PGF-la production has not yet been quantified), with a large peak occurring on Day 5, when PG production is higher than at any stage during the oestrous cycle. Day 5 is the day of implantation and so PG production in vitro by the rat uterus during early pregnancy and pseudopregnancy has been measured. In addition, the effects of indomethacin on implantation in the rat and the development of pregnancy up to Day 9 have been investigated.
Materials and Methods
Wistar rats were housed under controlled lighting conditions (lights on 08:00-20:00 h). Vaginal smears were taken daily and examined microscopically. Day 1 (oestrus) of the cycle was taken as the day of maximum cornification preceding the day of leucocytic infiltration. All rats used had shown regular 4-day cycles before being allocated to one of the following experiments. Experiment 1. On the afternoon of Day 4 of the cycle females were caged individually with vasectomized males. They were removed at 12:00 h on the following day, which then became Day 1 of pseudopregnancy. Mating was assumed to have taken place in the dark period, and pseudopregnancy was confirmed by the lack of subsequent oestrus and/or by the determination of peripheral plasma progesterone levels. Vaginal smears taken daily from 3 rats indicated that the length of pseudopregnancy (i.e. the period between two successive periods of oestrus) was 13 days in all 3 rats.
Other rats, lightly anaesthetized with ether, were bled by cardiac puncture at 10:00 h on each of Days 4-6 of pseudopregnancy (4 rats/day). The blood was withdrawn into a heparinized syringe (10 i.u./ml) and centrifuged at 600 g for 5 min. Plasma samples were stored at -20°C before being assayed for progesterone. After killing the rats, by stunning then incising the neck, the uterus was removed, weighed, homogenized in 15 ml Krebs' solution, incubated at 37°C for 60 min, and the prostaglandins extracted, by methods previously described (Mitchell, Poyser & Wilson, 1977; Fenwick et al, 1977) . The solvent extraction procedure used gives recoveries of 90% for PGF-2a and PGE-2 and 65-75% for 6-oxo-PGF-la (Poyser & Scott, 1980 (Dighe, Emslie, Henderson, Rutherford & Simon, 1975) . Although the antibody does not distinguish between PGF-2a and PGF-la, it is probable that only PGF-2a was being measured because the pseudopregnant rat uterus synthesizes very little PGF-la (Fenwick et al, 1977) . The detection limit of the assay was 50 pg per tube. PGE-2 was measured using an antibody raised in rabbits and purchased from the Pasteur Institute (Paris). It has previously been tested and found suitable for use in this laboratory (Mitchell et al, 1977) . Cross-reactivity with PGE-1 is low (6-6%). The detection limit of the assay was 20 pg per tube. 6-Oxo-PGF-la was measured by an antibody raised in rabbits (Dighe, Jones & Poyser, 1978; Poyser & Scott, 1980) . The detection limit was 30 pg per tube. The cross-reactivities of the 6-oxo-PGF-la, PGE-2 antibodies with other prostaglandins have been reported by Poyser & Scott (1980) . Plasma progesterone levels in rats were measured as described previously (Fenwick et al, 1977) . The detection limit of the assay was 35 pg per tube. The inter-assay coefficients of variation for the PGF-2a, PGE-2, 6-oxo-PGF-la and progesterone radioimmunoassays were 8-4, 4-2, 6-1 and 7-2% respectively. In each assay, biological samples were assayed in duplicate. If the coefficient of variation between the values obtained in each pair of results exceeded 15%, then the biological sample was re-assayed. However, for most samples this intra-assay coefficient of variation between paired values was <10%.
Measurement of 6-oxo-PGF-la by gas chromatography-mass spectrometry (GC-MS). The radioimmunoassay results for 6-oxo-PGF-la production in Exps 1 and 2 were checked by GC-MS. Assays were carried out on a VG Micromass 7070F double-focussing gas chromatogram-mass spectrometer, using the multiple ion detector unit. The column was packed with 3% OV1 on Supelcoport (Supelco Inc., Belleforte, U.S.A.), the helium gas flow was 30 ml/min and the column temperature was 260°C. The methyl ester-butyloxime-trimethylsilyl (Me-BuO-TMS) derivative of 6-oxo-PGF-la was prepared as described previously (Fenwick et al, 1977) .
To two-fifths of each biological sample were added 400 ng 3,3,4,4-tetradeuterated-6-oxo-PGF-la (2H4-6-oxo-PGF-l) as internal standard. The Me-BuO-TMS derivative of the dried samples was then formed. One-quarter of each prepared derivative was injected into the apparatus and the m/e ions at 491 and 495, corresponding to 6-oxo-PGF-la and 2H4-6-oxo-PGF-la (carbon value of 2nd isomers = 26-2), respectively, were monitored. Standard quantities of 0, 12-5, 25, 50, 100 and 200 ng 6-oxo-PGF-la and 100 ng 2H4-6-oxo-PGF-la (as the Me-BuO-TMS derivatives) were also injected into the apparatus and the ions at mle 491 and 495 were recorded. A standard curve (which in fact was a straight line) was obtained by plotting the ratio of the heights of the peaks produced by the ions at 491 and 495 against the standard quantities of 6-oxo-PGF-la. By finding this ratio for each sample, the amount of 6-oxo-PGF-la in the sample was determined from the standard curve. fig.  2 . The production of PGE-2 and 6-oxo-PGF-la peaked on Day 5, as in pseudopregnancy. Uterine PGF-2a production significantly increased from Days 2 to 3 of pregnancy, but then showed little variation until decreasing on Day 7. There was no peak equivalent to that for pseudopregnant rats on Day 5. 6-Oxo-PGF-la production was 5-6 times higher than PGF-2a or PGE-2 production and values obtained by radioimmunoassay were similar to those obtained by GC-MS (Table 1) .
Peripheral plasma progesterone concentrations (mean ± s.e.m. for 5 observations) during early pregnancy were 33 ± 4, 53 ± 4, 94 ± 20, 70 ± 9 and 77 ± 10 ng/ml, on Days 3, 4, 5, 6
and 7 respectively, and agree with values reported previously (Wiest, Kidwell & Balogh, 1968) . 6-9 ±2-1 7-8 ±0-5 9-4 ± 1-0 11-6 ± 0-9 Metabolism significantly increased with time (P < 0-001). The addition of NAD+ and excess PGF-2a had no significant effect. Experiment 5. Pregnant rats treated with indomethacin had no uterine 'dye reaction' sites when examined at 02:00 h on Day 6, in contrast to control rats (Table 4) . Some indomethacin-treated rats showed small dark spots in the endometrium which may have been blood clots. Pregnant rats treated with indomethacin and examined at 10:00 h on Day 6 had numbers of'dye reaction' sites/uterine horn similar to those of control rats. Peripheral plasma progesterone concentrations in pregnant rats treated with indomethacin (Text- fig. 3 ) were significantly lower than those in control rats at all times studied. Experiment 6. Indomethacin treatment reduced the numbers of implantation sites/uterine horn and uterine weight (Table 4) . When implantation had occurred, the implanted blastocysts were visibly smaller than in control rats, and in 2 of the 4 animals were bunched at the cervical end of the uterine horns. Control rats had evenly spaced implanted blastocysts.
Discussion
The major PG formed by uterine homogenates of rats early in pseudopregnancy and pregnancy was 6-oxo-PGF-la, the stable metabolite of prostacyclin (PGI-2); production peaked on Day 5 in both reproductive states. Uterine PGE-2 production was lower both during pregnancy and pseudopregnancy, again peaking on Day 5. Uterine PGF-2a production was also lower than 6-oxo-PGF-la production, but only peaked on Day 5 in pseudopregnant rats. There was no increase on this day in pregnant rats.
Changes in PG production are probably due to changes in PG synthesizing capacity of the tissue, for 2 reasons. Basal levels of PGs in the uterus are low, therefore fresh synthesis of prostaglandins must have taken place during incubation. Metabolism of PGF-2a by the pregnant uterus was also low and showed no difference on Day 5, so changes in PG metabolism could not account for changes in PGF production. Metabolism of PGF-2a by the pregnant rat uterus did show a small increase on Days 6 and 7, as reported by Flower (1976) . Metabolism of PGE-2 and PGI-2 by the pregnant rat uterus is also likely to be low as the same enzymes are involved. Oestradiol stimulates an increase in PG production by the uterus (Naylor & Poyser, 1975; Ham, Cirillo, Zanetti & Kuehl, 1975; Wlodawer, Kindahl & Hamberg, 1976) . The increase in plasma concentration of oestradiol early on Day 4 (Shaikh, 1971) (Fenwick et al, 1977) . However, in the pregnant rat, the ovary may not be the only source of increased oestradiol output.
A5-3ß-Hydroxysteroid dehydrogenase and oestradiol-17 ß-hydroxysteroid dehydrogenase ac¬ tivities are first detectable in the blastocyst on Day 4, peak on Day 5 and decline on Day 6 . If these changes in enzyme activities reflect changes in steroid synthesis, oestradiol and other steroid hormones synthesized by the blastocyst may alter uterine PG production. The presence of the blastocyst certainly does appear to affect uterine PG synthesis, since PGF-2a production by the pregnant uterus is lower on Day 5 compared with production by the pseudopregnant uterus.
These studies suggest a role for PGI-2 and PGE-2 in implantation in the rat. The levels of these 2 PGs are higher at the implantation site than in other uterine areas (Kennedy, 1977; Kennedy & Zamecnik, 1978) . Changes at the site of implantation have been linked to an inflammatory process (Horan, 1971 (Kennedy, 1979a, b) . The negative result obtained by Kennedy (1979b) (Elzayat & Stylos, 1974; El-Banna, Sacher & Schilling, 1976; Hoffman, 1978) .
In some of the rats treated with indomethacin the implanting blastocysts were bunched at the cervical end, as previously observed by Kennedy (1977) . Local increases in uterine PG production within a uterine horn could be responsible for the normally even spacing of the blastocysts at implantation. In the indomethacin-treated rats, plasma progesterone con¬ centrations were significantly reduced at Days 6-9 of pregnancy. Kennedy (1977) 
